This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Boehringer Ingelheim Pharma GmbH.
Reference
Olson AL, et al. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA. Advances in Therapy : 12 May 2020. Available from: URL: http://doi.org/10.1007/s12325-020-01380-4
Rights and permissions
About this article
Cite this article
Progressive fibrosing interstitial lung disease: high care needs, high costs. PharmacoEcon Outcomes News 855, 25 (2020). https://doi.org/10.1007/s40274-020-6890-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6890-6